Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 12/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.55 |
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15869350 | 1.00 | TRPV4 (0.56) | TRPV4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6944897 | 0.93 | TRPV4 (0.56) | TRPV4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1402437 | 0.91 | TRPV4 (0.61) | TRPV4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5440161 | 0.86 | AR (0.49) | TRPV4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9977584 | 0.85 | AR (0.51) | PDE4APDE4BPDE4CPDE4DAR | |
| SCHEMBL509522 | 0.85 | AR (0.66) | PDE4APDE4BPDE4CPDE4DAR | |
| SCHEMBL29490258 | 0.85 | AR (0.66) | PDE4APDE4BPDE4CPDE4DAR | |
| SCHEMBL15364954 | 0.83 | AR (0.49) | TRPV4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6197396 | 0.82 | MAPK1 (0.49) | TRPV4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1823391 | 0.82 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684604-A | Preparation method of intermediate impurity and finished product impurity of apremilast | 江苏正大清江制药有限公司 | 2024-09-24 | — | — | CN | claimed |
| EP-3702347-B1 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | AMGEN EUROPE GMBH (CH) | 2023-11-08 | — | — | EP | claimed |
| US-10913717-B2 | Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2021-02-09 | — | — | US | claimed |
| CN-107941945-B | Detection method of 3-ethoxy-4-methoxybenzonitrile | 中山奕安泰医药科技有限公司 | 2020-12-22 | — | — | CN | claimed |
| US-10774041-B2 | Process for the preparation of apremilast | Rao, Davuluri Ramamohan (IN) | 2020-09-15 | — | — | US | claimed |
| EP-3702347-A1 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | Amgen (Europe) GmbH (CH) | 2020-09-02 | — | — | EP | claimed |
| CN-107976501-B | Detection method of 1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine | 中山奕安泰医药科技有限公司 | 2020-08-25 | — | — | CN | claimed |
| US-20200109114-A1 | SOLID STATE FORMS OF N-[2-[(I S)-1 -(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYL SULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-L H-ISOINDOL-4-YL]ACETAMIDE AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2020-04-09 | — | — | US | claimed |
| EP-3312156-B1 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | CELGENE CORP (US) | 2019-06-05 | — | — | EP | claimed |
| US-20190071401-A1 | Improved Process for the Preparation of Apremilast | DAVULURI RAMAMOHAN RAO (IN) | 2019-03-07 | — | — | US | claimed |
| US-20160186093-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2016-06-30 | — | — | US | claimed |
| US-9309487-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2016-04-12 | — | — | US | claimed |
| US-9187417-B2 | Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine | CELGENE CORPORATION (US) | 2015-11-17 | — | — | US | claimed |
| EP-2817288-A2 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | Celgene Corporation (US) | 2014-12-31 | — | — | EP | claimed |
| US-20140378360-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2014-12-25 | — | — | US | claimed |
| EP-2723841-A1 | PERFUME SYSTEMS | The Procter and Gamble Company (US) | 2014-04-30 | — | — | EP | claimed |
| WO-2013126360-A2 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | CELGENE CORPORATION (US) | 2013-08-29 | — | — | WO | claimed |
| US-20130217918-A1 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | CELGENE CORPORATION (US) | 2013-08-22 | — | — | US | claimed |
| US-20120329696-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE COMPANY, THE | 2012-12-27 | — | — | US | claimed |
| WO-2012177357-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2012-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913717-B2 | Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof | SULT1A1, SULT2A1, SULT1E1 | TRPV4 1407/4885PDE4A 2312/4885PDE4B 2424/4885 |
| US-20200109114-A1 | SOLID STATE FORMS OF N-[2-[(I S)-1 -(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYL SULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-L H-ISOINDOL-4-YL]ACETAMIDE AND PROCESS FOR PREPARATION THEREOF | SULT1A1, SULT2A1, SULT1E1 | TRPV4 1407/4885PDE4A 2312/4885PDE4B 2424/4885 |
| US-10774041-B2 | Process for the preparation of apremilast | CMA1, APRT, QDPR | TRPV4 3126/4885PDE4A 150/4885PDE4B 185/4885 |
| US-20130217918-A1 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | TNF, SMS, SRM | TRPV4 4641/4885PDE4A 2008/4885PDE4B 2317/4885 |
| US-20120329696-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | TRPV4 134/4885PDE4A 188/4885PDE4B 371/4885 |
| US-20190071401-A1 | Improved Process for the Preparation of Apremilast | QDPR, CMA1, ACE | TRPV4 3620/4885PDE4A 181/4885PDE4B 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.